


Nephrotic syndrome ASPN September13th, 2019


1





















































- · Pneumococcal vaccines (PCV13, PPSV23)
- · Annual influenza vaccine
- · Defer live vaccines until prednisone dose is < 0.5mg/kg/day
- · Live vaccines contraindicated in patients taking corticosteroid-sparing immunosuppressives
- Child should avoid direct exposure to GI, urinary, or respiratory secretions of contacts who receive live vaccines, for 3-6 weeks after contact
- · Give IVIG (or VZIG: Varicella IgG) if non-immune patient is exposed to varicella (close contact)



## Relapses


- Partial remission


   proteinuria 200-3500 mg/day
   more than 50% reduction in proteinuria from baseline and < 3500 mg/day</li>


  Non responder: less than 50% reduction in
- proteinuria and still >3500 mg/day

22

Steroid Dependent Steroid Sensitive Nephrotic Syndrome		
Agent	Advantages	Disadvantages
Cyclophosphamide	Prolonged remission off therapy Inexpensive	Less effective in SD SSNS Monitoring of blood count during therapy Potential serious short- and long-term adverse effects Only one course should be given
Chlorambucil	Prolonged remission off therapy Inexpensive	Less effective in SD SSNS Monitoring of blood count during therapy Potential serious adverse effects Only one course should be given Not approved for SSNS in some countries
Levamisole	Few adverse effects Generally inexpensive	Continued treatment required to maintain remission Limited availability Not approved for SSNS in some countries
Cyclosporine	Prolonged remissions in some children with SD SSNS	Continued treatment often required to maintain remission Expensive Nephrotoxic Cosmetic side-effects
Tacrolimus	Prolonged remissions in some children with SD SSNS	Continued treatment often required to maintain remission Expensive Nephrotoxic Risk of diabetes mellitus Not approved for SSNS in some countries
Mycophenolate mofetil	Prolonged remissions in some children with FR and SD SSNS Few adverse effects	Continued treatment often required to maintain remission Probably less effective than CNIs Expensive Not approved for SSNS in some countries








•Age: Children 2-10 years more likely to respond


Histology, biopsies
 MCNS: 90% therapy responsive
 FSGS: 30% therapy responsive
 Congenital Nephrotic syndrome and most familial cases therapy unresponsive

Race
 African American children more likely to have therapy
 unresponsive disease (APOL1 mutations)







27


















34















41










46





48

